Glaukos Co. (NYSE:GKOS) Insider Sells $502,630.24 in Stock

Glaukos Co. (NYSE:GKOS) insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $126.03 on Friday. The business’s 50-day moving average price is $152.75 and its two-hundred day moving average price is $139.25. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a one year low of $83.90 and a one year high of $163.71. The company has a market capitalization of $6.95 billion, a P/E ratio of -41.73 and a beta of 1.04.

Glaukos (NYSE:GKOS) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Analysts anticipate that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on GKOS shares. Needham & Company LLC boosted their price objective on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research note on Friday. Wells Fargo & Company boosted their target price on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday. BTIG Research boosted their target price on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Truist Financial boosted their target price on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $180.00 target price (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $163.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GKOS. State of Wyoming boosted its stake in shares of Glaukos by 2.3% during the 4th quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier’s stock worth $487,000 after acquiring an additional 72 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Glaukos by 3.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier’s stock worth $345,000 after acquiring an additional 73 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of Glaukos by 1.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock worth $1,252,000 after acquiring an additional 89 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Glaukos by 2.8% during the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock worth $495,000 after acquiring an additional 91 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in shares of Glaukos by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $4,003,000 after acquiring an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.